# Theravance Biopharma, Inc. · Edgar & Edgarette company card

> Theravance Biopharma grew revenue 66.9% in FY2025 to $107 million, operating margin -3.4%, in line with the -3.8% median for pharmaceutical preparations, equity 61.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1583107 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/1583107) · [JSON](https://www.pops4.com/boards/company/1583107.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $107M |
| Revenue growth, 1 year | 66.9% |
| Revenue growth per year | 18.1% |
| Operating margin | -3.4% (prior year -72.9%) |
| Net margin | 98.5% |
| Operating cash flow | $239M |
| Capital spending | $42,000 |
| Free cash flow | $238M |
| Cash | $168M |
| Long-term debt | — |
| Total assets | $486M |
| Total equity | $297M |
| Equity ÷ assets | 61.1% |
| Return on equity | 35.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.96 (distress zone)
- Piotroski F: 7 of 9 (solid)
- Health Harbor boat: Old boat · three warning signs · filed restructuring or exit costs in the last 12 months; operating loss: a margin of -3.4% in FY2025; revenue is hard to predict: its 80% range is ±30%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $107.5M (FY2025). Experience: revenue up 66.9% on the year, up 18.1% a year over 4 years; operating margin -3.4%, up from -72.9%. Soundness: equity 61.1% of assets, return on equity 35.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $114.3M and $212.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $97.7M to $250.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -3.4% against a -3.8% median; growth 66.9% against 13.7%.

Range logged 2026-09-24, receipt fbb982561e62f9fe, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-09-23 ([filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/0001104659-26-109979-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-03-03 ([filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/0001104659-26-022572-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-09-23 ([filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/0001104659-26-109979-index.htm))

## Recent filings

- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/0001104659-26-109979-index.htm)
- 8-K · filed 2026-09-18 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/0001104659-26-108980-index.htm)
- 8-K · filed 2026-09-10 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/0001104659-26-106567-index.htm)
- 8-K · filed 2026-08-25 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926100860/0001104659-26-100860-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926093773/0001104659-26-093773-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583107/000110465926093066/0001104659-26-093066-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001583107.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1583107

## Cite

POPS4, Edgar & Edgarette: Theravance Biopharma, Inc. company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/1583107. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.